Melatonin Induces Analgesic Effects through MT
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
pharmacotherapy | decrease | NP alleviation | patients with neuropathic pain | - | serves as a primary approach | #1 |
pharmacotherapy | no change | NP alleviation | patients with neuropathic pain | - | efficacy often remains suboptimal | #2 |
Melatonin (MLT) | increase | sleep | - | - | has long been associated with promoting and maintaining | #3 |
Melatonin (MLT) | decrease | pain | - | - | recent studies suggest analgesic effects | #4 |
Melatonin (MLT) | decrease | NP symptoms | mice with spared nerve injury (SNI) NP model | - | observed a considerable, dose-dependent alleviation in | #5 |
Melatonin (MLT) | neutral | MLT-related receptor 2 (MT2) | mice with spared nerve injury (SNI) NP model | - | NP management of MLT is selectively mediated by | #6 |
Neuropathic pain (NP) represents a considerable clinical challenge, profoundly impacting patients' quality of life. Presently, pharmacotherapy serves as a primary approach for NP alleviation, yet its efficacy often remains suboptimal. Melatonin (MLT), a biologically active compound secreted by the pineal gland, has long been associated with promoting and maintaining sleep. Although recent studies suggest analgesic effects of MLT, the underlying mechanism remains largely unknown, particularly its impact on the cortex. In this study, we induced an NP model in mice through spared nerve injury (SNI) and observed a considerable, dose-dependent alleviation in NP symptoms following intraperitoneal or anterior cingulate cortex (ACC) administration of MLT. Our findings further indicated that the NP management of MLT is selectively mediated by MLT-related receptor 2 (MT